Jasper Therapeutics, Inc. (JSPR) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US4718712023

Price
13.68 USD
Market cap
15.17 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

Jasper Therapeutics, Inc. financials

Fiscal year2025
Operating income-83.88 m USD
EBIT-77.54 m USD
Net income-75.80 m USD
Diluted EPS – continuing operations-3.95 USD

Full history since 2019, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Jasper Therapeutics, Inc.

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of biologic agents to enhance the outcomes in patients with immunologically-driven disorders. The company is based in Redwood City, California.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.